PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
A systematic review of 24 studies (including 705 individuals) examined the efficacy of ibogaine and noribogaine for SUDs [PMID:35012793].
Ibogaine has been proposed as a drug cessation treatment with activities targeting opioids, cocaine, and alcohol [PMID:28194562]. Animal models show it can blunt self-administration of opiates, cocaine, amphetamines, and nicotine [PMID:30216039, PMID:40895173].
Water extract of iboga root bark was studied for potential alleviating effects on high-fat diet-induced hyperglycemia in C57BL/6J mice [PMID:30582133].
Safety & adverse effects
Drug interactions
Evidence summary
PubMed sources
- 1.PMID: 35012793 (2022) — A systematic literature review of clinical trials and therapeutic applications of ibogaine. · Journal of substance abuse treatment
- 2.PMID: 28194562 (2017) — The Iboga Alkaloids. · Progress in the chemistry of organic natural products
- 3.PMID: 30216039 (2018) — DARK Classics in Chemical Neuroscience: Ibogaine. · ACS chemical neuroscience
- 4.PMID: 39304653 (2024) — Oxa-Iboga alkaloids lack cardiac risk and disrupt opioid use in animal models. · Nature communications
- 5.PMID: 26827885 (2016) — Monoterpenoid Bisindole Alkaloids. · The Alkaloids. Chemistry and biology